Antibe Therapeutics Inc.
ATE
Ранг среди акций
#31892
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Цена акции
$0.21483059
Последняя синхронизация: 2024-05-07
Рыночная капитализация
$11.13M
Изменение (1 день)
0.34%
Изменение (1 год)
-0.36%
Страна
CA
Торговля Antibe Therapeutics Inc. (ATE)
Категория
Healthcare
Коэффициент P/S для Antibe Therapeutics Inc. (ATE)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Antibe Therapeutics Inc., текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Antibe Therapeutics Inc. с 2026 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| Недостаточно данных для указанных дат. | ||
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 3.82 | - |
US
|
|
| 2.78 | - |
IE
|
|
| 4.18 | - |
US
|
|
| 2.97 | - |
US
|
|
| - | - |
DE
|
